• Accelero_Spring_2017_1.jpg
  • Accelero_Spring_2017_2.jpg
  • Accelero_Spring_2017_3.jpg
  • Accelero_Spring_2017_4.jpg
  • Accelero_Spring_2017_5.jpg
  • Accelero_Spring_2017_6.jpg
  • Accelero_Spring_2017_7.jpg
  • Accelero_Spring_2017_8.jpg
  • Accelero_Spring_2017_9.jpg

Accelero Bioanalytics GmbH, a young Biotech business focussing on innovative custom-made bioanalytical services, reported today that the company´s first financial year ended on 31 December 2012 was successfully closed with profit.

Earning before tax and provisions was 5 percent of business sales in 2012.

In comparison to the period of the preceding year, the business volume in Q1-2013 continued to grow by 50 percent. The client base increased by 100 percent, which created a continuously expanding bioanalytical study pipeline. Exciting projects were initiated in the last months to encounter the need for assay development capabilities in the challenging field of nucleic acid based therapeutics, gene expression analysis, and genetic characterization of cell banks intended for use in active biopharmaceuticals production.

In addition to the pleasant business development in Q1-2013, Accelero Bioanalytics corporate website enjoyed increasing attention. Site visits went up by 25 percent, with about 1.700 page views per month. More than 35 percent of those were from English speaking countries, only 30 percent were from Germany.

For the financial year 2013 Accelero Bioanalytics GmbH expects to nearly double turnover and revenues. The corporate strategy of sustainable growth on the basis of positive cash flow will be consequently followed.

Berlin-based Accelero Bioanalytics GmbH was founded in 2011. The company was approved for genetic engineering safety level S2 projects, and offers cloning services as well as the bioanalysis of preclinical, clinical, and environmental samples in BSL2 laboratories fully compliant to Good Laboratory Practice (GLP).